Brind.

AI stocks benefit from Trump-era tariffs and onshoring, while Relay Therapeutics and OPEX report corporate updates.

2 reports, 1 independent Updated Aug 26

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AI stocks benefit from Trump-era tariffs and onshoring, while Relay Therapeutics and OPEX report corporate updates.

Who's involved

What this event is mainly about

Relay Therapeutics Donald Trump

Keep exploring

The entities involved

Relay Therapeutics
company in Cambridge, United States

Nothing else this week.
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Both South Carolina and Alabama are facing challenges to Republican redistricting initiatives, with federal court rulings impacting Donald Trump's efforts.05:57
- Trump held rallies in Kansas while accusing Fox News of sabotage, amid projections of Democrats seizing the House.05:50

Coverage

Newest first; wire copies grouped

Aug 26Insider MonkeyLeerink Partners Reiterates a Buy Rating on Relay Therapeutics (RLAY) With a $12 PT Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the top strong buy stocks under $5 to buy now. Leerink Partners an
Jun 25Unknown outlet